Antisense oligonucleotides targeted to the human α folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment

Molecular Cancer Therapeutics

Volumn 3, Issue 12, 2004, Pages 1505-1512

  Jhaveri, Mona S ^a   Rait, Antonina S ^a   Chung, Koong Nah ^b   Trepel, Jane B ^c   Chang, Esther H ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FOLATE RECEPTOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY DNA; DOXORUBICIN; FOLATE RECEPTOR; ISOPROTEIN; LIPOSOME; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; TRANSFERRIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL STRAIN KB; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIZATION; DRUG TARGETING; GENE SEQUENCE; GENETIC COMPLEMENTATION; HUMAN; HUMAN CELL; NASOPHARYNX CARCINOMA; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REDUCTION; TUMOR CELL;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BREAST NEOPLASMS; CARRIER PROTEINS; CELL PROLIFERATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; FOLIC ACID; HUMANS; LIPOSOMES; OLIGONUCLEOTIDES, ANTISENSE; RECEPTORS, CELL SURFACE; TRANSFERRIN; TUMOR CELLS, CULTURED;

EID: 12344303295     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Henderson GB. Folate-binding proteins. Annu Rev Nutr 1990;10: 319-35.
2. Antony AC. Folate receptors. Annu Rev Nutr 1996;16:501-21.
3. Kane MA, Elwood PC, Portillo RM, et al. Influence on immunoreactive folate-binding proteins of extracellular folate concentration in cultured human cells. J Clin Invest 1988;81:1398-406.
4. Wagner C. Folate-binding proteins. Nutr Rev 1985;43:293-9.
5. Rijnboutt S, Jansen G, Posthuma G, Hynes JB, Schornagel JH, Strous GJ. Endocytosis of GPI-linked membrane folate receptor-α. J Cell Biol 1996;132:35-47.
6. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992;52:3396-401.
7. Garin-Chesa P, Campbell I, Saigo PE, Lewis JL, Old LJ, Rettig WJ. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol 1993;142:557-67.
8. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994;73:2432-43.
9. Tomassetti A, Bottero F, Mazzi M, Miotti S, Colnaghi MI, Canevari S. Molecular requirements for attachment of the glycosylphosphatidylinositol anchor to the human α folate receptor. J Cell Biochem 1999;72:111-8.
10. Rothberg KG, Ying YS, Kolhouse JF, Kamen BA, Anderson RG. The glycophospholipid-linked folate receptor internalizes folate without entering the clathrin-coated pit endocytic pathway. J Cell Biol 1990;110: 637-49.
11. Chung KN, Roberts S, Kim CH, Kirassova M, Trepel J, Elwood PC. Rapid turnover and impaired cell-surface expression of the human folate receptor in mouse L(tk-) fibroblasts, a cell line defective in glycosylphosphatidylinositol tail synthesis. Arch Biochem Biophys 1995;322: 228-34.
12. Ilangumaran S, He HT, Hoessli DC. Microdomains in lymphocyte signalling: beyond GPI-anchored proteins. Immunol Today 2000;21:2-7.
13. Horejsi V, Drbal K, Cebecauer M, et al. GPI-microdomains: a role in signalling via immunoreceptors. Immunol Today 1999;20:356-61.
14. Miotti S, Bagnoli M, Tomassetti A, Colnaghi MI, Canevari S. Interaction of folate receptor with signaling molecules lyn and G(α)(i-3) in detergent-resistant complexes from the ovary carcinoma cell line IGROV1. J Cell Sci 2000;113:349-57.
15. Bottero F, Tomassetti A, Canevari S, Miotti S, Menard S, Colnaghi MI. Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res 1993;53:5791-6.
16. Xu L, Pirollo KF, Tang WH, Rait A, Chang EH. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther 1999;10:2941-52.
17. Xu L, Pirollo KF, Tang WH, Rait A, Chang EH. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in human tumor regression. Tumor Target 1999;4:92-114.
18. McHugh M, Cheng YC. Demonstration of a high affinity folate binder in human cell membranes and its characterization in cultured human KB cells. J Biol Chem 1979;254:11312-8.
19. Chung KN, Saikawa Y, Paik TH, et al. Stable transfectants of human MCF-7 breast cancer cells with increased levels of the human folate receptor exhibit an increased sensitivity to antifolates. J Clin Invest 1993; 91:1289-94.
20. Saikawa Y, Knight CB, Saikawa T, Page ST, Chabner BA, Elwood PC. Decreased expression of the human folate receptor mediates transport-defective methotrexate resistance in KB cells. J Biol Chem 1993;268: 5293-301.
21. Roberts SJ, Chung KN, Nachmanoff K, Elwood PC. Tissue-specific promoters of the α human folate receptor gene yield transcripts with divergent 5′ leader sequences and different translational efficiencies. Biochem J 1997;326:439-47.
22. Rait AS, Pirollo KF, Rait V, Krygier JE, Xiang L, Chang EH. Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer. Cancer Gene Ther 2001;8:728-39.
23. Pinard MF, Jolivet J, Ratnam M, et al. Functional aspects of membrane folate receptors in human breast cancer cells with transport-related resistance to methotrexate. Cancer Chemother Pharmacol 1996; 38:281-8.
24. Cristiano RJ, Curiel DT. Strategies to accomplish gene delivery via the receptor-mediated endocytosis pathway. Cancer Gene Ther 1996;3: 49-57.
25. Cheng PW. Receptor ligand-facilitated gene transfer: enhancement of liposome-mediated gene transfer and expression by transferrin. Hum Gene Ther 1996;7:275-82.
26. Thorstensen K, Romslo I. The transferrin receptor: its diagnostic value and its potential as therapeutic target. Scand J Clin Lab Invest Suppl 1993; 215:113-20.
27. Miyamoto T, Tanaka N, Eishi Y, Amagasa T. Transferrin receptor in oral tumors. Int J Oral Maxillofac Surg 1994;23:430-3.
28. Keer HN, Kozlowski JM, Tsai YC, Lee C, McEwan RN, Grayhack JT. Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo. J Urol 1990;143:381-5.
29. Inoue T, Cavanaugh PG, Steck PA, Brunner N, Nicolson GL. Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. J Cell Physiol 1993;156:212-7.
30. Crooke ST. Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta 1999;1489:31-44.
31. Walder RY, Walder JA. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci U S A 1988;85:5011-5.
32. Wu M, Gunning W, Ratnam M. Expression of folate receptor type α in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev 1999; 8:775-82.
33. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 2000;41:147-62.
34. Crippa F, Buraggi GL, Di Re E, et al. Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody. Eur J Cancer 1991; 27:724-9.
35. 67Ga-deferoxamine-folate, a potential radiopharmaceutical for tumor imaging. Bioconjug Chem 1996;7:56-62.
36. Mathias CJ, Wang S, Lee RJ, Waters DJ, Low PS, Green MA. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J Nucl Med 1996;37: 1003-8.
37. 67Ga-deferoxamine-folate to folate-receptor-positive human KB tumor xenografts. Nucl Med Biol 1999;26:23-5.
38. Burgstaller P, Jenne A, Blind M. Aptamers and aptazymes: accelerating small molecule drug discovery. Curr Opin Drug Discov Devel 2002; 5:690-700.
39. Joshi PJ, Fisher TS, Prasad VR. Anti-HIV inhibitors based on nucleic acids: emergence of aptamers as potent antivirals. Curr Drug Targets Infect Disord 2003;3:383-400.
40. Campbell IG, Jones TA, Foulkes WD, Trowsdale J. Folate-binding protein is a marker for ovarian cancer. Cancer Res 1991;51:5329-38.
41. Plentl AA, Friedman EA. Lymphatic system of the female genitalia. The morphologic basis of oncologic diagnosis and therapy. Major Probl Obstet Gynecol 1971;2:1-223.
42. Fuks Z. Patterns of spread of ovarian carcinoma: relation to therapeutic strategies. Adv Biosci 1980;26:39-51.
43. Gibbs DD, Gore ME. Pursuit of optimum outcomes in ovarian cancer: methodological approaches to therapy. Drugs 2001;61:1103-20.